Full-Time

LIS Software Engineer

Confirmed live in the last 24 hours

Veracyte

Veracyte

501-1,000 employees

Develops genomic tests for cancer diagnosis

Biotechnology
Healthcare

Compensation Overview

$140k - $175kAnnually

+ Bonus + Incentives + Restricted Stock Units

Senior

San Bruno, CA, USA

The company will consider candidates from the West Coast.

Category
Backend Engineering
Full-Stack Engineering
Software Engineering
Required Skills
Python
GraphQL

You match the following Veracyte's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Proficiency in Python for application development, scripting, and integration tasks.
  • Experience working with or implementing Laboratory Information Systems (LIS) or related technologies.
  • Familiarity with laboratory workflows, data management, and regulatory requirements.
  • Strong understanding of software development best practices, including version control and testing frameworks.
  • Proficient in GraphQL and working with relational databases.
  • Excellent analytical and problem-solving skills with attention to detail.
  • Strong communication and collaboration abilities to work effectively with cross-functional teams.
Responsibilities
  • Develop, configure, and maintain LIS solutions to support laboratory operations.
  • Design and implement integrations between LIS/LIMS systems and external applications or instruments using Python.
  • Analyze laboratory workflows and collaborate with stakeholders to understand and improve system functionalities.
  • Perform system customizations, including scripting and automation, to enhance efficiency and data accuracy.
  • Troubleshoot, debug, and resolve system issues in a timely manner to ensure minimal disruption to laboratory operations.
  • Work closely with Quality Assurance and Compliance teams to ensure adherence to regulatory and validation requirements.
  • Provide technical support and training to end-users for LIS functionalities.
  • Document system configurations, processes, and technical specifications for internal and regulatory use.
  • Assist with the migration, upgrade, or deployment of LIS/LIMS systems and associated software.
Desired Qualifications
  • Prior experience working with LIMS systems such as STARLIMS, Labbit or LabVantage.
  • Familiarity with cloud-based data solutions or platforms (e.g., AWS, Azure, or GCP).
  • Knowledge of data integration frameworks (e.g., REST APIs, SQS/ActiveMQ).
  • Understanding of laboratory compliance standards like CLIA, CAP, or FDA.
  • Hands-on experience with automation tools or laboratory instruments.

Veracyte develops and sells advanced genomic tests for the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples like nasal swabs or tissue biopsies, providing insights into the presence and progression of cancer. This allows healthcare providers, such as hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte stands out from competitors by focusing on non-invasive testing methods and continuously investing in research to expand their product offerings. Their goal is to improve cancer diagnosis accuracy, leading to better patient outcomes and more efficient healthcare resource use.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$69.4M

Headquarters

San Francisco, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven genomic testing enhances precision in diverse populations.
  • Board expansion with Brent Shafer and Tom Miller fosters strategic innovation.
  • Recognition as a top workplace attracts talent and drives innovation.

What critics are saying

  • Potential bias in tests due to initial development on White American males.
  • MRD assay launch in 2026 may face acceptance challenges from payers.
  • ClearLab launch could encounter regulatory hurdles affecting market penetration.

What makes Veracyte unique

  • Veracyte specializes in non-invasive genomic tests for early cancer detection.
  • The Decipher Prostate genomic classifier aids in prostate cancer prognosis.
  • Veracyte's nasal swab test improves early lung cancer risk assessment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-2%
MarketBeat
Dec 21st, 2024
HighTower Advisors LLC Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)

HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).

Inside Precision Medicine
Oct 3rd, 2024
Veracyte's RNA Genetic Test Predicts Black Men's Aggressive Prostate Cancer

That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.

Investing.com
Sep 4th, 2024
Veracyte expands board with two new members

SOUTH SAN FRANCISCO, Calif. - Veracyte, Inc. (NASDAQ:VCYT), a global cancer diagnostics company, announced today the addition of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.

Stock Titan
Sep 4th, 2024
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.

Investing.com
Aug 28th, 2024
Veracyte stock gets target upgrade by Needham, highlights improved financial outlook

Looking ahead, Veracyte plans to launch an MRD assay in 2026 and is working on policy updates with commercial payers for LCD products.